NCT00003384

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (Agus or Agcus) As a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 684 (actual)
• Sponsor: Gynecologic Oncology Group · Network
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This diagnostic trial is studying the presence of a specific protein as a potential biomarker of cervical dysplasia and/or cancer. The presence of specific proteins may allow a doctor to determine whether a patient has cervical dysplasia and/or cancer.

Detailed description

OBJECTIVES: I. Evaluate the utility of MN protein, a novel tumor-associated antigen, as a potential diagnostic biomarker for cervical glandular and/or squamous neoplasia in patients with a cytologic diagnosis of atypical glandular cells of undetermined significance (AGUS). II. Measure the frequency and type of cervical pathology associated with the diagnosis of AGUS in these patients. III. Determine whether the presence of a high-risk type of human papilloma virus (HPV) in a ThinPrep cervical cell specimen predicts the presence of cervical glandular and/or squamous cell neoplasia in these patients. IV. Determine the relationship between MN antigen expression and the presence of high-risk HPV in these patients. OUTLINE: This is a multicenter study. Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression. Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks.

Conditions

• Precancerous Condition
• Stage 0 Cervical Cancer

Interventions

Type	Name	Description
OTHER	Cervical Papanicolaou Test	Undergo Pap smear
PROCEDURE	Conization	Undergo cone biopsy
OTHER	Laboratory Biomarker Analysis	Correlative studies

Timeline

• Start date: 1998-09-01
• Primary completion: 2011-01-01
• First posted: 2003-01-27
• Last updated: 2015-05-29

Locations

1 site across 1 country: United States